Erik Harris - 03 Feb 2022 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role: Director
Signature: /s/ Tyler Nielsen, by power of attorney
Issuer symbol: DNLI
Transactions as of: 03 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 07 Feb 2022, 17:54:54 UTC
Previous filing: 18 Oct 2021
Next filing: 14 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNLI	Common Stock	Award	$0	+6,869		$0.000000	6,869	03 Feb 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNLI	Stock Option (right to buy)	Award	$0	+20,607		$0.000000	20,607	03 Feb 2022	Common Stock	20,607	$33.74	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2	25% of the restricted stock units shall vest on February 3, 2023 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a non-employee director of the Issuer through each such date.
F3	25% of the shares subject to the option shall vest on February 3, 2023, and an additional 1/48 of the shares subject to the option vest each month thereafter, subject to the Reporting Person remaining a non-employee director of the Issuer through each such date